Press Releases

Press Releases

Date Title
09/27/21 Vaxart Appoints Dr. James F. Cummings as Chief Medical Officer
Dr. Cummings Brings Nearly Three Decades of Experience to New Role SOUTH SAN FRANCISCO, Calif. , Sept. 27, 2021 /PRNewswire/ --  Vaxart, Inc. (NASDAQ: VXRT), today announced the appointment of James F. Cummings , M.D., as the Company's Chief Medical Officer (CMO). Dr.
09/22/21 Vaxart To Present at Upcoming Vaccine Conferences
One of Company's Senior Scientists To Present at ID Week 2021 and 15th Vaccine Congress SOUTH SAN FRANCISCO, Calif. , Sept. 22, 2021 /PRNewswire/ --  Vaxart, Inc. (NASDAQ: VXRT), today announced that one of the company's senior scientists, Susan Johnson PhD, will present at both ID Week 2021 and
09/21/21 Vaxart Announces Creation of Manufacturing and Quality Advisory Board
Leaders in the Pharmaceutical Industry To Advise Vaxart As It Advances Its Manufacturing Capabilities SOUTH SAN FRANCISCO, Calif. , Sept. 21, 2021 /PRNewswire/ --  Vaxart, Inc. (NASDAQ: VXRT), today announced that it has formed a Manufacturing and Quality Advisory Board.       "We are very excited
09/20/21 Vaxart to Present at the 2021 Cantor Virtual Global Healthcare Conference on Thursday, September 30
SOUTH SAN FRANCISCO , Sept. 20, 2021 /PRNewswire/ -- Vaxart, Inc. (NASDAQ: VXRT) today announced that Chief Executive Officer Andrei Floroiu and Chief Scientific Officer Dr. Sean Tucker will present at the 2021 Cantor Virtual Global Healthcare Conference at 10:40 a.m.
09/07/21 Vaxart to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
SOUTH SAN FRANCISCO, Calif. , Sept. 7, 2021 /PRNewswire/ --  Vaxart, Inc. (Nasdaq: VXRT) today announced that Andrei Floroiu , President and CEO, and Dr. Sean Tucker , SVP and Chief Scientific Officer, will present at the H.C. Wainwright 23 rd Annual Global Investor Conference taking place Sept.
08/23/21 Vaxart Announces Highly Regarded Biotech Executive Julie M. Cherrington, Ph.D., Joins Board of Directors
Dr. Cherrington brings decades of research and development experience and executive leadership to Vaxart's Board SOUTH SAN FRANCISCO, Calif. , Aug. 23, 2021 /PRNewswire/ -- Vaxart, Inc. (NASDAQ: VXRT) today announced the addition of Julie M. Cherrington , Ph.D., to the company's board of directors.
08/19/21 Vaxart Announces Creation of New Scientific and Clinical Advisory Board
Leaders in Health Care, Vaccines, and Academic Research to Advise Vaxart as it Progresses Its Ground-Breaking Technology SOUTH SAN FRANCISCO, Calif. , Aug. 19, 2021 /PRNewswire/ -- Vaxart, Inc. (NASDAQ: VXRT), today announced the creation of an eight-member Scientific and Clinical Advisory Board . 
08/05/21 Vaxart Provides Business Update and Reports Second Quarter 2021 Financial Results
Company makes advances with its disruptive oral vaccine portfolio Cash, cash equivalents, and marketable securities of $198.9 million as of June 30, 2021 SOUTH SAN FRANCISCO, Calif. , Aug. 5, 2021 /PRNewswire/ --  Vaxart, Inc. (Nasdaq: VXRT) issued its business update today for the second quarter
08/02/21 FDA Clears Vaxart's IND Application for S-Only Oral Tablet COVID-19 Vaccine Candidate
Vaccine candidate expressing S-only protein produced higher serum antibodies than construct expressing both S and N in NHP study Phase II clinical trial with S-only candidate to begin in 2H21 Development of this and other S-only constructs will proceed in parallel with that of S+N construct, as
07/29/21 Vaxart Reports Boosting Immune Responses in Subjects Previously Vaccinated by a Vaxart Vaccine
First booster clinical study by Vaxart shows boosted immune responses similar to original responses with Vaxart vaccine Findings have potential implications for Vaxart's COVID-19 oral vaccine program SOUTH SAN FRANCISCO, Calif. , July 29, 2021 /PRNewswire/ --  Vaxart, Inc.